



## DAFTAR PUSTAKA

- Arfian, N. *et al.* (2019). Chlorogenic acid attenuates kidney ischemic/reperfusion injury via reducing inflammation, tubular injury, and myofibroblast formation. *BioMed Research International*, 2019. doi: 10.1155/2019/5423703.
- Bagdas, D. *et al.* (2014). Pharmacologic overview of systemic chlorogenic acid therapy on experimental wound healing. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 387(11), pp. 1101–1116. doi: 10.1007/s00210-014-1034-9.
- Bao, L. *et al.* (2018). Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF- $\kappa$ B pathways. *International Immunopharmacology*. Elsevier, 54(October 2017), pp. 245–253. doi: 10.1016/j.intimp.2017.11.021.
- Bianconi, V. *et al.* (2018). The regulation and importance of monocyte chemoattractant protein-1. *Current Opinion in Hematology*, 25(1), pp. 44–51. doi: 10.1097/MOH.0000000000000389.
- Calle, P. and Hotter, G. (2020). Macrophage Phenotype and Fibrosis in Diabetic Nephropathy. *International Journal of Molecular Sciences*, 21(8), p. 2806. doi: 10.3390/ijms21082806.
- Cao, Q., Harris, D. C. H. and Wang, Y. (2015). Macrophages in Kidney Injury, Inflammation, and Fibrosis. *Physiology*, 30(3), pp. 183–194. doi: 10.1152/physiol.00046.2014.
- Charlton, A. *et al.* (2020). Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. *Biology*, 10(1), p. 18. doi: 10.3390/biology10010018.
- Chen, L. *et al.* (2018). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6), pp. 7204–7218. Available at: [www.impactjournals.com/oncotarget/](http://www.impactjournals.com/oncotarget/).
- Cheon, C. K. (2018). Understanding of type 1 diabetes mellitus: What we know and where we go. *Korean Journal of Pediatrics*, 61(10), pp. 307–314. doi: 10.3345/kjp.2018.06870.
- Chistiakov, D. A. *et al.* (2017). CD68/macrosialin: Not just a histochemical marker. *Laboratory Investigation*. Nature Publishing Group, 97(1), pp. 4–13. doi: 10.1038/labinvest.2016.116.
- Chow, F. Y. *et al.* (2006). Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. *Kidney International*, 69(1), pp. 73–80. doi: 10.1038/sj.ki.5000014.
- Coffin, A. *et al.* (2015). Radioanatomy of the retroperitoneal space. *Diagnostic and*



- Interventional Imaging*. Elsevier Masson SAS, 96(2), pp. 171–186. doi: 10.1016/j.diii.2014.06.015.
- Eddy, A. A. (2004). Proteinuria and interstitial injury. *Nephrology Dialysis Transplantation*, 19(2), pp. 277–281. doi: 10.1093/ndt/gfg533.
- Eroschenko, V. P. (2012). 12st ed Atlas Histologi diFiore. Jakarta: EGC
- Feng, Y. *et al.* (2016). Chlorogenic acid protects d -galactose-induced liver and kidney injury via antioxidation and anti-inflammation effects in mice. *Pharmaceutical Biology*, 54(6), pp. 1027–1034. doi: 10.3109/13880209.2015.1093510.
- Gheith, O. *et al.* (2016). Diabetic kidney disease: world wide difference of prevalence and risk factors. *Journal of nephro pharmacology*, 5(1), pp. 49–56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28197499> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5297507>.
- Guyton JE HAC. (2016). Guyton and Hall textbook of medical physiology. 13th ed. Philadelphia: PA Saunders/Elsevier.
- Haller, H. *et al.* (2016). Monocyte chemoattractant protein-1 and the kidney. *Current Opinion in Nephrology and Hypertension*, 25(1), pp. 42–49. doi: 10.1097/MNH.0000000000000186.
- Hwang, S. J. *et al.* (2014). Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide- stimulated RAW 264.7 cells. *Inflammation Research*, 63(1), pp. 81–90. doi: 10.1007/s00011-013-0674-4.
- Insel, R. A. *et al.* (2015). Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association. *Diabetes Care*, pp. 1964–1974. doi: 10.2337/dc15-1419.
- Kahanovitz, L., Sluss, P. M. and Russell, S. J. (2017). Type 1 diabetes-a clinical perspective. *Point of Care*, 16(1), pp. 37–40. doi: 10.1097/POC.0000000000000125.
- Kolseth, I. B. M. *et al.* (2017). Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy. *Journal of Diabetes and its Complications*. Elsevier Inc., 31(1), pp. 245–252. doi: 10.1016/j.jdiacomp.2016.06.029.
- Li, Y. *et al.* (2018). Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. *International Journal of Molecular Medicine*, 41(5), pp. 2629–2639. doi: 10.3892/ijmm.2018.3501.
- Lim, A. K. H. (2014). Diabetic nephropathy – Complications and treatment. *International Journal of Nephrology and Renovascular Disease*, 7, pp. 361–381. doi: 10.2147/IJNRD.S40172.



- Lim, A. K. H. and Tesch, G. H. (2012). Inflammation in Diabetic Nephropathy. *Mediators of Inflammation*, 2012, pp. 1–12. doi: 10.1155/2012/146154.
- Lin, H. C. *et al.* (2014). 5-lipoxygenase inhibitors attenuate TNF- $\alpha$ -Induced inflammation in human synovial fibroblasts. *PLoS ONE*, 9(9). doi: 10.1371/journal.pone.0107890.
- Linda A DiMeglio , Carmella Evans-Molina, R. A. O. (2019). Type 1 Diabetes. HHS Public Access', *Physiology & behavior*, 176(3), pp. 139–148. doi: 10.1016/S0140-6736(18)31320-5.Type.
- Ma, Y., Gao, M. and Liu, D. (2015). Chlorogenic Acid Improves High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. *Pharmaceutical Research*, 32(4), pp. 1200–1209. doi: 10.1007/s11095-014-1526-9.
- Matoba, K. *et al.* (2019). Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. *International Journal of Molecular Sciences*, 20(14), p. 3393. doi: 10.3390/ijms20143393.
- Mescher, A.L. (2016). Junquiera's Basic Histology Text and Atlas 14th Edition. New York: McGraw-Hill.
- Miao, M. and Xiang, L. (2020) *Pharmacological action and potential targets of chlorogenic acid*. 1st edn, *Advances in Pharmacology*. 1st edn. Elsevier Inc. doi: 10.1016/bs.apha.2019.12.002.
- Mobasser, M. *et al.* (2020). Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. *Health Promotion Perspectives*, 10(2), pp. 98–115. doi: 10.34172/hpp.2020.18.
- Moore, K., Agur, A. & Dalley, A. (2014). Clinically oriented anatomy. 7th ed. Philadelphia: Lippincott Williams & Wilkins
- Nishi, Ahad, A. and Kumar, P. (2013). Protective effect of chlorogenic acid against diabetic nephropathy in high fat diet/streptozotocin induced type-2 diabetic rats. *International Journal of Pharmacy and Pharmaceutical Sciences*, 5(SUPPL. 2), pp. 489–495.
- Quan, Y. *et al.* (2011). High glucose stimulates TNF $\alpha$  and MCP-1 expression in rat microglia via ROS and NF- $\kappa$ B pathways. *Acta Pharmacologica Sinica*, pp. 188–193. doi: 10.1038/aps.2010.174.
- Queeley, G. L. and Campbell, E. S. (2018). Comparing treatment modalities for end-stage renal disease: A meta-analysis. *American Health and Drug Benefits*, 11(3), pp. 118–125. doi: 10.1016/j.jval.2014.03.1690.
- Ren, L. (2019). Protective effect of ganoderic acid against the streptozotocin induced diabetes, inflammation, hyperlipidemia and microbiota imbalance in diabetic rats. *Saudi Journal of Biological Sciences*. King Saud University, 26(8), pp. 1961–1972. doi: 10.1016/j.sjbs.2019.07.005.



- Ross, M., & Pawlina, W. (2015). *Histology, a Text and Atlas, Seventh Edition*. Journal of Chemical Information and Modeling (Vol. 53). <https://doi.org/10.1017/CBO9781107415324.004>
- Satirapoj, B. *et al.* (2018). Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease. *BMC Nephrology*. BMC Nephrology, 19(1), pp. 1–10. doi: 10.1186/s12882-018-1043-x.
- Sherwood, L. (2016). *Human Physiology from Cells to Systems Eighth Edition*. Virginia: Brooks/Cole.
- Soetikno, V. *et al.* (2011). Curcumin ameliorates macrophage infiltration by inhibiting NF- $\kappa$ B activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. *Nutrition and Metabolism*. BioMed Central Ltd, 8(1), p. 35. doi: 10.1186/1743-7075-8-35.
- Standring, S. (2016). *Gray's anatomy*. 41<sup>st</sup> ed. Philadelphia: Elsevier Limited.
- Stefanello, N. *et al.* (2019). Coffee, caffeine, chlorogenic acid, and the purinergic system. *Food and Chemical Toxicology*. Elsevier Ltd, 123, pp. 298–313. doi: 10.1016/j.fct.2018.10.005.
- Sulaiman, M. K. (2019). Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management. *Diabetology and Metabolic Syndrome*. BioMed Central, 11(1), pp. 1–5. doi: 10.1186/s13098-019-0403-4.
- Taghavi, Y. *et al.* (2019). Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations. *Journal of Cell Communication and Signaling*, 13(4), pp. 451–462. doi: 10.1007/s12079-018-00500-8.
- Tang, P. C. T. *et al.* (2020). The emerging role of innate immunity in chronic kidney diseases. *International Journal of Molecular Sciences*, 21(11), pp. 1–19. doi: 10.3390/ijms21114018.
- Tortora, G. & Derrickson, B. (2014). *Principles of anatomy & physiology*. 13th ed. Hoboken, N.J.: John Wiley & Sons.
- Toth-Manikowski, S. and Atta, M. G. (2015). Diabetic kidney disease: Pathophysiology and therapeutic targets. *Journal of Diabetes Research*. Hindawi Publishing Corporation, 2015. doi: 10.1155/2015/697010.
- Typiak, M. and Piwowska, A. (2021). Antiinflammatory Actions of Klotho: Implications for Therapy of Diabetic Nephropathy. *International Journal of Molecular Sciences*. International Journal of Molecular Sciences, 22(2), p. 956. doi: 10.3390/ijms22020956.
- Wang, Y. *et al.* (2019). M1 and M2 macrophage polarization and potentially



- therapeutic naturally occurring compounds. *International Immunopharmacology*. Elsevier, 70(January), pp. 459–466. doi: 10.1016/j.intimp.2019.02.050.
- Wang, Z. S. *et al.* (2015). Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. *BMC Nephrology*, 16(1), pp. 1–9. doi: 10.1186/s12882-015-0031-7.
- White, N. H. (2015). Long-term Outcomes in Youths with Diabetes Mellitus. *Pediatric Clinics of North America*, 62(4), pp. 889–909. doi: 10.1016/j.pcl.2015.04.004.
- Wu, J. and Yan, L. J. (2015). Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic  $\beta$  cell glucotoxicity. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, pp. 181–188. doi: 10.2147/DMSO.S82272.
- Wu, Y. L. *et al.* (2013). Risk factors and primary prevention trials for type 1 diabetes. *International Journal of Biological Sciences*, 9(6), pp. 666–679. doi: 10.7150/ijbs.6610.
- Yan, Y. *et al.* (2020). Use of Chlorogenic Acid against Diabetes Mellitus and Its Complications. *Journal of Immunology Research*, 2020. doi: 10.1155/2020/9680508.
- Yang, X., Wang, Y. and Gao, G. (2016). High glucose induces rat mesangial cells proliferation and MCP-1 expression via ROS-mediated activation of NF- $\kappa$ B pathway, which is inhibited by eleutheroside E. *Journal of Receptors and Signal Transduction*, 36(2), pp. 152–157. doi: 10.3109/10799893.2015.1061002.
- Yang, Z. *et al.* (2018). miR-374a regulates inflammatory response in diabetic nephropathy by targeting MCP-1 expression. *Frontiers in Pharmacology*, 9(AUG), pp. 1–8. doi: 10.3389/fphar.2018.00900.
- Yu, J. *et al.* (2019). High-mobility group nucleosome-binding protein 1 mediates renal fibrosis correlating with macrophages accumulation and epithelial-to-mesenchymal transition in diabetic nephropathy mice model. *Kidney and Blood Pressure Research*, 44(3), pp. 331–343. doi: 10.1159/000499877.
- Zhang, C. *et al.* (2020). Circular RNA circPPM1F modulates M1 macrophage activation and pancreatic islet inflammation in type 1 diabetes mellitus. *Theranostics*, 10(24), pp. 10908–10924. doi: 10.7150/thno.48264.
- Zhang, Q. *et al.* (2016). Protective effects of leflunomide on renal lesions in a rat model of diabetic nephropathy. *Renal Failure*, 38(1), pp. 124–130. doi: 10.3109/0886022X.2015.1105024.
- Zhang, X. L. *et al.* (2014). Vitamin D prevents podocyte injury via regulation of macrophage M1/M2 phenotype in diabetic nephropathy rats. *Endocrinology (United States)*, 155(12), pp. 4939–4950. doi: 10.1210/en.2014-1020.



Zhong, Y. *et al.* (2014). Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats. *PLoS ONE*, 9(1), pp. 1–9. doi: 10.1371/journal.pone.0085690.